[1]刘鹏江,邓 琦.伊布替尼治慢性淋巴细胞白血病的研究[J].医学信息,2020,33(22):48-50.[doi:10.3969/j.issn.1006-1959.2020.22.015]
　LIU Peng-jiang,DENG Qi.Research of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia[J].Medical Information,2020,33(22):48-50.[doi:10.3969/j.issn.1006-1959.2020.22.015]
点击复制

伊布替尼治慢性淋巴细胞白血病的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年22期
页码:
48-50
栏目:
综述
出版日期:
2020-11-15

文章信息/Info

Title:
Research of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia
文章编号:
1006-1959（2020）22-0048-03
作者:
刘鹏江; 邓 琦
（天津市第一中心医院血液科，天津 300192）
Author(s):
LIU Peng-jiang; DENG Qi
(Department of Hematology,Tianjin First Central Hospital,Tianjin 300192,China)
关键词:
伊布替尼; 慢性淋巴细胞白血病; 安全性; 有效性
Keywords:
Ibrutinib; Chronic lymphocytic leukemia; Safety; Effectiveness
分类号:
R733.72；R563.13
DOI:
10.3969/j.issn.1006-1959.2020.22.015
文献标志码:
A
摘要:
慢性淋巴细胞白血病是临床常见的恶性肿瘤，原发于造血组织，是一种有特定免疫表型特征的成熟B淋巴细胞克隆增殖性肿瘤，以淋巴细胞在外周血液、骨髓、脾脏、淋巴结聚集为特征。目前，该疾病发病机制尚未完全明确，治疗方法较多，无统一标准。化学免疫治疗仍然是标准治疗选择，但对于复发、难治、存在高危细胞遗传学等因素的患者其预后较差。随着临床对慢性淋巴细胞白血病发病机制的深入研究，各种治疗药物相继问世。伊布替尼的出现，为慢性淋巴细胞白血病治疗提供新的研究方向，且在临床取得一定效果。但其治疗有效性、安全性等方面尚未存在争议。本文现就慢性淋巴细胞白血病的发病机制、临床表现及伊布替尼在其治疗中的应用进行综述。
Abstract:
Chronic lymphocytic leukemia is a common clinical malignant tumor. It originates from hematopoietic tissues. It is a mature B lymphocyte clonal proliferative tumor with specific immunophenotypic characteristics. It is characterized by the accumulation of lymphocytes in peripheral blood, bone marrow, spleen, and lymph nodes. feature. At present, the pathogenesis of the disease is not yet fully clear, there are many treatment methods, and there is no uniform standard. Chemoimmunotherapy is still the standard treatment option, but the prognosis is poor for patients with relapsed, refractory, and high-risk cytogenetics. With the in-depth clinical research on the pathogenesis of chronic lymphocytic leukemia, various therapeutic drugs have come out one after another. The emergence of ibrutinib provides a new research direction for the treatment of chronic lymphocytic leukemia, and has achieved certain clinical effects. However, there is no controversy regarding its therapeutic effectiveness and safety. This article reviews the pathogenesis, clinical manifestations and application of Ibrutinib in the treatment of chronic lymphocytic leukemia.

参考文献/References:

[1]刘澎.复旦大学附属中山医院慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊疗规范[J].中国临床医学,2018,25(1):157-160.[2]王欣,周香香.慢性淋巴细胞白血病的临床分期与治疗[J].临床血液学杂志,2014,27(9):732-736.[3]王艳萍,卢愿,仲任,等.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的不良反应及影响因素分析[J].山东医药,2015(39):90-92.[4]Nabhan C,Rosen ST.Chronic lymphocytic leukemia:aclinical review[J].JAMA,2014,312(21): 2265-2276.[5]李姮,熊文婕,刘慧敏,等.利妥昔单抗联合化疗治疗慢性淋巴细胞白血病的疗效分析[J].中国医学科学院学报,2017,39(6):800-805.[6]Edelmqnn J,Holzmann K,Miller F,et al.High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations[J].Blood,2014,120(24):4783-4794.[7]Hillmen P,Gribben JG,Follows GA,et al.Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia[J].J Clin Oncol,2014,32(12):1236-1241.[8]Goede V,Fischer K,Busch R,et al.Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions[J].N Engl J Med,2014,370(12):1101-1110.[9]鲍萍萍,吴春晓,张敏璐,等.上海市白血病主要亚型发病特征和趋势分析[J].诊断学理论与实践,2017,5(16):484-491.[10]朱海波,赵明峰,李玉明,等.初治急性髓系白血病患者首次诱导化疗后血小板计数与预后的关系研究[J].中国全科医学,2016,19(29):3528-3533.[11]严雪梅.去甲氧柔红霉素和高三尖杉酯碱对阿糖胞苷治疗复发难治性急性髓系白血病患者疗效的影响[J].医疗装备,2018,31(6):113-114.[12]Hallek M.Chronic lymphocytic leukemia:2017 update on diagnosis,risk stratification,and treatment[J].American Journal of Hematology,2017,92(9):946-965.[13]李晋文,孙晓蕊,张晓磊,等.来那度胺联合利妥昔单抗治疗套细胞淋巴瘤的疗效及安全性分析[J].临床药物治疗杂志,2018,16(5):64-69[14]Cerhan JR,Slager SL.Familial predisposition and genetic risk factors for lymphoma[J].Blood,2015,126(20):2265-2273.[15]Baliakas P,Mattsson M,Stamatopoulos K,et al.Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed[J].Journal of Internal Medicine,2016,279(4):347-357.[16]葛星瑶,鄢金柱,张超,等.环磷酰胺和氟达拉滨联合利妥昔单抗治疗慢性淋巴细胞白血病疗效与安全性的Meta分析[J].肿瘤学杂志,2018,24(2):129-134.[17]周楠,周颖,赵侠,等.治疗慢性淋巴细胞白血病新药obinutuzumab的药理作用及临床评价[J].中国新药杂志,2014,23(11):1227-1229.[18]de Claro RA,Mcginn KM,Verdun N,et al.FDA Approval:Ibrutinib for Patients withPreviously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia[J].Clinical Cancer Research,2015,21(16):3586-3590.[19]李建勇,徐卫.我们如何诊断和治疗慢性淋巴细胞白血病[J].中华血液学杂志,2018,39(7):529-532.[20]王莉,缪扣荣,范磊,等.减低强度预处理的异基因造血干细胞移植治疗伴p53基因异常的慢性淋巴细胞白血病[J].中华血液学杂志,2016,37(4):308-312.[21]Kater AP,Spiering M,Liu RD,et al.Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia:a multicenter phase 2 study[J].Leuk Res,2014,38(1):34-41.

相似文献/References:

[1]石 沁,欧阳红梅,宋建新.慢性淋巴细胞白血病患者骨髓INF-γ、IL-2、IL-4、IL-10及IL-1β水平的变化及意义[J].医学信息,2018,31(17):149.[doi:10.3969/j.issn.1006-1959.2018.17.047]
　SHI Qin,OUYANG Hong-mei,SONG Jian-xin.Changes and Significance of IFN-γ,IL-2,IL-4,IL-10 and IL-1β in Marrow of Patients with Chronic Lymphocytic Leukemia[J].Medical Information,2018,31(22):149.[doi:10.3969/j.issn.1006-1959.2018.17.047]
[2]刘婕妤,方智辉,李文克,等.伊布替尼与氟达拉滨联合环磷酰胺治疗慢性淋巴细胞白血病的疗效[J].医学信息,2020,33(13):148.[doi:10.3969/j.issn.1006-1959.2020.13.044]
　LIU Jie-yu,FANG Zhi-hui,LI Wen-ke,et al.Efficacy of Ibrutinib and Fludarabine Combined with Cyclophosphamide in the Treatment of Chronic Lymphocytic Leukemia[J].Medical Information,2020,33(22):148.[doi:10.3969/j.issn.1006-1959.2020.13.044]

更新日期/Last Update: 1900-01-01